… gefitinib. In the Iressa Survival Evaluation in Lung Cancer (ISEL) study, however, gefitinib
failed to prolong survival in patients with advanced NSCLC after the failure of at least one prior …

… treatment after the failure of gefitinib. The present study retrospectively evaluated the
clinical value of continuing gefitinib administration after the failure of initial gefitinib treatment. …

… The use of erlotinib after gefitinib failure in patients with non-small cell lung cancer (NSCLC)
is … clinical reports to better understand the effectiveness of erlotinib after failure of gefitinib. …

… Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this … of gefitinib and
erlotinib was evaluated as the second-line therapy for advanced non-small cell lung cancer (…

… NSCLC patient population after failure of chemotherapy.13, 14 … Lung Cancer, IDEAL 1 and
2) demonstrated that gefitinib was … Evaluation in Lung Cancer trial comparing gefitinib with …

… In our study, The DCR of erlotinib after gefitinib failure was similar to that in Cho’s study.
Most patients who benefit from erlotinib had also benefited from prior gefitinib treatment, but we …

… lung cancer (NSCLC) after failure of gefitinib therapy. Pre-clinical studies have demonstrated
that gefitinib-… can be used as a treatment option for patients failing gefitinib monotherapy. …

… activity against advanced or recurrent non-small cell lung cancer (NSCLC). However, most …
of gefitinib in our limited study (p = 0.036). In 9 of 12 responders, gefitinib treatment failed due …

… lung adenocarcinoma with previous treatment failure on … major cancer conferences using
keywords “NSCLC”, “gefitinib”, “… with non-small-cell lung cancer (NSCLC) after chemotherapy …

… in Lung cancer), gefitinib failed to prolong survival compared with placebo in patients with
advanced NSCLC who had failed … which predict to response to gefitinib. Two types of somatic …